Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Concert Pharmaceuticals, a clinical stage biotechnology company creating novel and differentiated small molecule drugs, has entered into a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR).
Subscribe to our email newsletter
The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert’s DCE Platform (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury (TBI).
Concert and WRAIR will share costs on the preclinical efficacy evaluation of the compound.
WRAIR Center of Excellence for Military Psychiatry and Neuroscience’s Brain Trauma Neuroprotection and Neuroplasticity Branch chief Frank Tortella said his laboratory conducts basic and applied research on mechanisms and pathophysiology of brain injury, with a specific focus on developing improved diagnostics and novel neuroprotective therapeutics.
Concert president and CEO Roger Tung said that the partners will further evaluate this novel compound, identify and treat important unmet medical needs such as TBI.